Dr. Chris Chen, CEO of WuXi Biologics, discusses the evolving contract development and manufacturing organization landscape in this contributed article.
Three biopharma developers, including the Institute of Science Tokyo, selected the CDMO’s Yokohama site for cell therapy process development and manufacturing support.
The agreement gives the Hong Kong-based pharmaceutical company exclusive rights to use the TfR1 platform in up to two neurodegenerative disease programs.
This presentation addresses key considerations for developing and validating ADC-specific analytical methods, including DAR distribution, free payload, conjugational heterogeneity, product-related impurities and functional potency.